First clinical application of silicon-based [¹⁸F]siPSMA-14 in prostate cancer patients: A proof-of-concept study

Abstract

Aim

Silicon-based ligands are of interest in increasingly used Prostate-specific membrane antigen (PSMA) tracers for prostate cancer (PCa) staging due to their simple and scalable production. Here, we present first data on dosimetry and biodistribution of the novel PSMA-specific tracer [¹⁸F]siPSMA-14.

Methods

Seven PCa patients referred for PSMA-PET/CT imaging were imaged at 60 and 120 min p.i. (T1 and T3), without forced diuresis, to assess organ absorbed (AD) and effective doses (ED). We matched seven of subsequent 134 patients imaged at 90 min. p. i. (T2) to the initial seven patients according to disease and patient characteristics. SUVs of organs and PCa lesions as well as target-to-non-target ratios (TnTR) were analyzed. Statistical analysis was done using paired t-tests and Mann-Whitney U tests.

Results

[¹⁸F]siPSMA-14 dosimetry showed an ED of 1.95E-02±0.25E-02 mSv/MBq with the highest AD in kidneys (1.40E-01±0.41E-01 mGy/MBq). Tracer uptake in lesions (SUVmax±SD) was intense in all patients and increased significantly over time (local lesions (intraprostatic lesions or local recurrences) T1: 10.6±4.5; T3: 14.0±5.9 (p=0.01); metastatic lesions: T1: 17.7±8.9; T3: 20.6±9.4 (p=0.01). PCa uptake at T2 was similar, without significant difference in interindividual comparison in local (T1 to T2: p=0.39; T2 to T3: p=1.0) and metastatic lesions (T1 to T2: p=0.79; T2 to T3: p=0.43).

Conclusion

[¹⁸F]siPSMA-14 showed moderate effective doses comparable to other 18F- and 68Ga-labeled PCa tracers even without forced diuresis. Uptake in PCa lesions was high and in line with data for other PSMA specific tracers. This suggests that PET imaging with[¹⁸F]siPSMA-14 is safe and effective even without forced diuresis with the advantage of a simple and scalable production.

Keywords

Oncology - prostate cancer - PET/CT - PSMA

Publication History

Received: 20 November 2024

Accepted after revision: 09 July 2025

Article published online:
05 September 2025

• References

• 1 von Eyben FE, Picchio M, von Eyben R. et al. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus 2018; 4: 686-693
• 2 Kuten J, Fahoum I, Savin Z. et al. Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J Nucl Med 2020; 61: 527-532
• 3 Rauscher I, Krönke M, König M. et al. Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2020; 61: 51-57
• 4 Research C for DE and. FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer. FDA 2021. Accessed October 03, 2022 at: www.fda.gov/drugs/news-events-human-drugs/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer
• 5 Research C for DE and. Drug Trials Snapshot: POSLUMA. FDA 2024. Accessed February 26, 2024 at: www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-posluma
• 6 Olivier P, Giraudet A-L, Skanjeti A. et al. Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study. J Nucl Med 2023; 64: 579-585
• 7 Surasi DS, Eiber M, Maurer T. et al. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). Eur Urol 2023; 84: 361-370
• 8 Ermert J, Neumaier B. The Radiopharmaceutical Chemistry of Fluorine-18: Nucleophilic Fluorinations. In: Lewis JS, Windhorst AD, Zeglis BM. , ed. Radiopharmaceutical Chemistry. Cham: Springer International Publishing; 2019: 273-283
• 9 McBride WJ, Sharkey RM, Karacay H. et al. A novel method of 18F radiolabeling for PET. J Nucl Med 2009; 50: 991-998
• 10 Jacobson O, Kiesewetter DO, Chen X. Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjug Chem 2015; 26: 1-18
• 11 Gens TA, Wethongton JA, Brosi AR. The Exchange of F18between Metallic Fluorides and Silicon Tetrafluoride. ACS Publications 2002. Accessed October 09, 2022 at: https://pubs.acs.org/doi/pdf/10.1021/j150570a030
• 12 Wurzer A, Di Carlo D, Schmidt A. et al. Radiohybrid Ligands: A Novel Tracer Concept Exemplified by 18F- or 68Ga-Labeled rhPSMA Inhibitors. J Nucl Med 2020; 61: 735-742
• 13 Schirrmacher R, Bradtmöller G, Schirrmacher E. et al. 18F-labeling of peptides by means of an organosilicon-based fluoride acceptor. Angew Chem Int Ed Engl 2006; 45: 6047-6050
• 14 Kostikov AP, Iovkova L, Chin J. et al. N-(4-(di-tert-butyl[¹⁸F]fluorosilyl)benzyl)-2-hydroxy-N,N-dimethylethylammonium bromide ([¹⁸F]SiFAN+Br−): A novel lead compound for the development of hydrophilic SiFA-based prosthetic groups for 18F-labeling. Journal of Fluorine Chemistry 2011; 132: 27-34
• 15 Niedermoser S, Chin J, Wängler C. et al. In Vivo Evaluation of 18F-SiFAlin–Modified TATE: A Potential Challenge for 68Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET. Journal of Nuclear Medicine 2015; 56: 1100-1105
• 16 Wurzer A, Di Carlo D, Herz M. et al. Automated synthesis of [¹⁸F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions. EJNMMI Radiopharm Chem 2021; 6: 4
• 17 Löffler J, Hamp C, Scheidhauer E. et al. Comparison of Quantification of Target-Specific Accumulation of [¹⁸F]F-siPSMA-14 in the HET-CAM Model and in Mice Using PET/MRI. Cancers (Basel) 2021; 13: 4007
• 18 Hardiansyah D, Yousefzadeh-Nowshahr E, Kind F. et al. Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [177Lu]Lu-PSMA-617 Therapy. Journal of Nuclear Medicine 2024; 65: 566-572
• 19 Hardiansyah D, Riana A, Beer AJ. et al. Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model. Z Med Phys 2023; 33: 70-81
• 20 Devasia TP, Dewaraja YK, Frey KA. et al. A Novel Time – Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE. Journal of Nuclear Medicine 2021; 62: 1118-1125
• 21 Siebinga H, de Wit-van der Veen BJ, Stokkel MDM. et al. Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review. Theranostics 2022; 12: 7804-7820
• 22 The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 2007; 37: 1-332
• 23 Giesel FL, Hadaschik B, Cardinale J. et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 2017; 44: 678-688
• 24 Cho SY, Gage KL, Mease RC. et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012; 53: 1883-1891
• 25 Afshar-Oromieh A, Hetzheim H, Kratochwil C. et al. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. J Nucl Med 2015; 56: 1697-1705
• 26 Afshar-Oromieh A, Hetzheim H, Kübler W. et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging 2016; 43: 1611-1620
• 27 Pfob CH, Ziegler S, Graner FP. et al. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 1962-1970
• 28 Szabo Z, Mena E, Rowe SP. et al. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol 2015; 17: 565-574
• 29 Tolvanen T, Kalliokoski K, Malaspina S. et al. Safety, Biodistribution, and Radiation Dosimetry of 18F-rhPSMA-7.3 in Healthy Adult Volunteers. J Nucl Med 2021; 62: 679-684
• 30 Langbein T, Wurzer A, Gafita A. et al. The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data. J Nucl Med 2022; 63: 742-745
• 31 Wondergem M, van der Zant FM, Knol RJJ. et al. 18F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution. J Nucl Med 2017; 58: 1797-1804
• 32 Schmuck S, Nordlohne S, von Klot C-A. et al. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging 2017; 44: 960-968